HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 25, No. 12, December 2021 – The Future of Us — Transforming Healthcare With Intelligent Machines       » Better Targeted Leukaemia Treatment With New Ferritin-Based Nanomedicine       » Manufacturing Chiral Medicine With New Cobalt-Based Catalyst       » SMART Develops 10-Minute Test for Detection of COVID Immunity       » From Plastics to Plants: Transforming Bio-Based Polymers into Fertilisers       » Creating Solar Cells and Glass From Wood and a Billion Tons of Biowaste      
Vol 25, No. 11, November 2021   |   Issue PDF view/purchase
EYE ON CHINA
New Strategy to Treat Acute Myeloid Leukaemia: Targeting Chaperone Proteins
The new inhibitor can effectively inhibit the overgrowth of leukaemia cells and shows potential to help overcome drug resistance.

Acute myeloid leukaemia (AML) is generally divided into subtypes based on their appearance and genetic mutation, with some forms of the cancer being more aggressive than others. The FLT3 mutation, for instance, causes a very aggressive form of leukaemia with high chances of relapse even after treatment because it encourages the overgrowth of abnormal leukaemia cells. Unfortunately, 20 to 30 per cent of people with acute myeloid leukaemia have this mutation and many chemotherapy drugs are not completely effective against cancers with the FLT3 mutation. Although FLT3 kinase inhibitors have demonstrated great success in clinical practice, prolonged treatments with the drug can lead to drug-acquired resistance.

Now, scientists led by Professor Liu Qingsong from the Hefei Institutes of Physical Sciences of the Chinese Academy of Sciences have discovered that the Bruton Tyrosine Kinase (BTK) inhibitor QL47 has potent anti-proliferative activity against FLT3-ITD (internal tandem duplication) positive AML cell lines and can induce FLT3-ITD protein degradation.

“What we are seeking is a new therapeutic strategy which imperative for FLT3-ITD-positive AML,” said Hu Chen, lead author of the study.

Heat shock proteins are major players in protein homeostasis and folding, especially for the overexpressed or mutated oncoproteins in cancers. Therefore, the team examined the interactions between QL47 and heat shock proteins. Surprisingly, QL47 was able to act on the heat shock protein HSP70. Through further study, the team was able to prove how QL47 works: the inhibitor irreversibly binds to heat shock protein HSP70 and inhibits its refolding activity, which in turn leads to the degradation of FLT3-ITD and suppresses the proliferation of FLT3-ITD positive AML cells.

“It is inducible HSP70 instead of constitutive expressed HSC70 that is important for FLT3 protein stabilisation and FLT3-ITD-positive cell viability,” revealed Dr. Hu.

Using primary patient cells and in vivo tumour models, the scientists evaluated the effects of QL47 from which they found that QL47 induced the degeneration of FLT3-ITD protein and cell apoptosis in primary patient cells. In a mice bone marrow engraftment model, QL47 significantly extended the survival of the animals. With this newly discovered HSP70 inhibitor and its potent antitumor efficacy, Dr. Hu believes that the QL47 “could potentially provide a novel strategy for FLT3-ITD-positive AML treatment” and overcome drug resistance.


Source: Hu et al. (2021). Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia. Signal Transduction and Targeted Therapy, 6, 334.

NEWS CRUNCH  
news Inaugural Asia Summit on Global Health highlights Hong Kong's advantages
news Asia Summit on Global Health (ASGH) 2021 — Shaping a Resilient and Sustainable Future
news TechInnovation 2021 Virtual Exhibition to Showcase Sustainable Energy, Food, and Healthcare Solutions
news A New Approach for Effective Gout Treatment
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy